Viracta Therapeutics Inc's Comment on Sales, Marketing and Customers
Viracta operates in the healthcare sector, serving prescription drug and medical device manufacturers, physicians, teaching hospitals, and other healthcare professionals. The company engages in research, sales, marketing, and distribution of products that may be reimbursed under federal healthcare programs including Medicare, Medicaid, and the Children’s Health Insurance Program. Viracta's business activities are regulated by federal, state, and foreign healthcare laws governing interactions with its customers and market segments.
Advancing Precision Oncology: Viracta Therapeutics’ Strategic Developments and Leadership Appointments In a noteworthy series of corporate and clinical advancements, Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company dedicated to the treatment and prevention of virus-associated cancers, has announced significant updates that emphasize its commitment to innovation and strategic growth. These developments not only highlight the company’s proactive approach to bolstering its leadership team but also underscore its progress in the clinical trial landscape, particularly for virus-associated cancers such as Epstein-Barr virus (EBV) related malignancies. Appointment of New ...
In a groundbreaking development, Viracta Therapeutics has announced the positive topline results from Stage 1 of the NAVAL-1 Trial. This trial evaluated the efficacy and safety of Nana-val (nanatinostat in combination with valganciclovir) in patients suffering from relapsed or refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma.The data obtained from this trial is truly remarkable. Patients in the Nana-val treatment arm achieved clinically meaningful anti-tumor responses, with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population. These figures increased even further to 71% and 29% respectively when considering the efficacy-evaluable popula...
In this article, we will discuss the recent achievement of Viracta Therapeutics, a leading biopharmaceutical company specializing in targeted treatments for cancer. Specifically, we will explore their progress in completing the second-stage enrollment into the peripheral T-cell lymphoma (PTCL) cohort of the NAVAL-1 trial. The article will outline the implications of this milestone and assess its impact on the company s strategy for expediting market access.Viracta Therapeutics recently announced the successful completion of the second-stage enrollment into the PTCL cohort of the NAVAL-1 trial. This development marks a significant step forward in the company s efforts to bring innovative therapies to patients...
Viracta Therapeutics Announces Promising Interim Data for Nana-val in Treating Epstein-Barr Virus-Positive Solid Tumors Viracta Therapeutics, a leading biotechnology company focused on innovative treatments for viral-associated cancers, has released interim data from their Phase 1b/2 clinical trial of Nana-val in patients with Epstein-Barr virus (EBV)-positive solid tumors. The results have shown confirmed tumor responses at higher dose levels, without any dose-limiting toxicities during dose escalation. This groundbreaking news is accompanied by new preclinical data that support the potential to achieve even greater efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val.
Viracta Therapeutics Inc’s Comment on Sales, Marketing and Customers
Viracta operates in the healthcare sector, serving prescription drug and medical device manufacturers, physicians, teaching hospitals, and other healthcare professionals. The company engages in research, sales, marketing, and distribution of products that may be reimbursed under federal healthcare programs including Medicare, Medicaid, and the Children’s Health Insurance Program. Viracta's business activities are regulated by federal, state, and foreign healthcare laws governing interactions with its customers and market segments.
Sources:
Viracta Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Viracta Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Viracta Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
